Recovering scientist turned early stage VC A biotech optimist fighting gravity

Surprising Resilience Of Private VC-Backed Biotech Markets
July 6, 2022

It’s biotech armageddon out there: with massive value destruction across public stocks, it’s clearly the worst market backdrop in over 20 years. Nothing like this pullback has happened in recent memory. This is way worse than the short “sky is

Leave a comment

This Too Shall Pass
June 28, 2022

By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC. Although I intend to shy away from the cult of celebrity, a recent clip from Tom Hanks resonated with me regarding the current state

Leave a comment

Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
June 21, 2022

By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by

Leave a comment

International Partnerships in Biotech: How Small Details Can Have a Big Impact
June 16, 2022

By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself setting out to do business in Japan. You step off the plane, check into

Leave a comment

Leading With Head And Heart – Navigating The Human Side Of Tough Decisions
June 2, 2022

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC 2022 has brought unique challenges for growing companies.  Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs,

Leave a comment

The Courage of Patients in Phase 1 Cancer Trials
May 31, 2022

By René Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC I had the opportunity to witness true courage as I met Chrissy Harding several times before she passed away from advanced lung cancer.

Leave a comment

Out On The (Cutting) Edge: How The Tools Of Extreme Survival Can Help Build A Biotech Company
May 18, 2022

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC  A couple of years ago, my husband returned from a business trip with a random gift for me. He was running through an airport

Leave a comment

Navigating Change: Observations from the Talent side of Professional Change
April 22, 2022

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Like many of you, I’m a consumer of biotech industry news. Multiple times of day I scour BioCentury, STAT,

Leave a comment

Responding To Tough Markets: Restructurings In Biotech
April 14, 2022

Another day, another “restructuring” – there’s been a flurry of press releases recently using phrases like “exploring strategic alternatives”, “extending the cash runway”, and “de-prioritizing” certain R&D programs. These announcements are obviously responses to the tough market environment. In every

Leave a comment

Take the Hors D’oeuvres When They’re Passed And Other Life Lessons From An “Old” CEO
April 7, 2022

By Natalie Holles, CEO of Third Harmonic Bio, as part of the From The Trenches feature of LifeSciVC Our company recently launched out of stealth with a trade media campaign in the usual outlets, which felt great until one article

Leave a comment

Biotech’s January Chill: Big Drop In New Startups
April 4, 2022

While the pace of startup formation in biotech has been accelerating over the past decade, early signs suggest the malaise in the markets is finding its way back into the venture creation ecosystem. Startups get formed, often in stealth, and

Leave a comment

Collaborating with Patient Advocacy Groups to Advance Rare Disease Awareness and Support
March 29, 2022

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Over my many years in the biopharma industry, working across disease areas, including orphan indications, I have learned that to impact patients’ lives

Leave a comment